Systematic review quantifies metabolic rebound after stopping GLP-1 drugs: weight regain is near-universal but variable
Meta-analysis quantifies metabolic rebound after GLP-1RA discontinuation: near-universal weight regain but variable rate, with HbA1c and cardiovascular parameters also worsening, though residual benefit may persist for some outcomes.
Quick Facts
What This Study Found
Weight regain: near-universal but variable rate. HbA1c: worsened. Cardiovascular parameters: deteriorated. Some residual benefit: may persist. Modifiers identified: treatment duration, lifestyle, individual factors. Comprehensive quantification of rebound.
Key Numbers
How They Did This
Systematic review and meta-analysis of GLP-1RA discontinuation studies in obesity, T2DM, and T1DM.
Why This Research Matters
Millions will eventually stop GLP-1 drugs (cost, shortage, personal choice). Quantifying what happens—and what modifies rebound—helps plan transitional care and manage expectations.
The Bigger Picture
Metabolic rebound after GLP-1 drug cessation is the Achilles heel of current obesity pharmacotherapy. This quantification enables evidence-based discontinuation planning and drives research into anti-rebound strategies.
What This Study Doesn't Tell Us
Heterogeneous discontinuation studies. Variable follow-up durations. No standardized rebound definition. Some studies small.
Questions This Raises
- ?How long do residual benefits persist after stopping?
- ?Can lifestyle intensification prevent rebound?
- ?Should GLP-1 drugs be lifelong or is tapering viable?
Trust & Context
- Key Stat:
- Rebound quantified Near-universal weight regain occurs after stopping GLP-1 drugs, with metabolic deterioration—but the rate varies and some benefits may persist, supporting planned transitions
- Evidence Grade:
- Systematic review and meta-analysis of available discontinuation data. Comprehensive quantification.
- Study Age:
- Published in 2025.
- Original Title:
- Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.
- Published In:
- EClinicalMedicine, 90, 103680 (2025)
- Authors:
- Tzang, Chih-Chen, Wu, Pei-Hsun, Luo, Chiao-An, Chen, Zi-Ting, Lee, Yi-Ting, Huang, Ewen Shengyao, Kang, Yuan-Fu, Lin, Wei-Chen, Tzang, Bor-Show, Hsu, Tsai-Ching
- Database ID:
- RPEP-13846
Evidence Hierarchy
Frequently Asked Questions
What happens when you stop GLP-1 drugs?
Weight regain is nearly universal, though the amount and speed vary. Blood sugar control worsens, and cardiovascular risk factors deteriorate. However, some benefits may persist partially. The rebound is not necessarily immediate—planning a gradual transition with lifestyle support can help minimize it.
Should GLP-1 drugs be taken forever?
This meta-analysis suggests that stopping leads to metabolic rebound, supporting long-term or lifelong use for many patients—consistent with treating obesity as a chronic disease. However, factors like treatment duration and lifestyle changes may modify the rebound, and some benefits appear to persist after stopping.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13846APA
Tzang, Chih-Chen; Wu, Pei-Hsun; Luo, Chiao-An; Chen, Zi-Ting; Lee, Yi-Ting; Huang, Ewen Shengyao; Kang, Yuan-Fu; Lin, Wei-Chen; Tzang, Bor-Show; Hsu, Tsai-Ching. (2025). Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.. EClinicalMedicine, 90, 103680. https://doi.org/10.1016/j.eclinm.2025.103680
MLA
Tzang, Chih-Chen, et al. "Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis.." EClinicalMedicine, 2025. https://doi.org/10.1016/j.eclinm.2025.103680
RethinkPeptides
RethinkPeptides Research Database. "Metabolic rebound after GLP-1 receptor agonist discontinuati..." RPEP-13846. Retrieved from https://rethinkpeptides.com/research/tzang-2025-metabolic-rebound-after-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.